Hepatic inflammation and progressive liver fibrosis in chronic liver disease

World Journal of Gastroenterology

Volumn 20, Issue 10, 2014, Pages 2515-2532

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiotensin receptors; Anti oxidants; Cirrhosis; Fibrosis; Inflammation; Investigational drugs; Treatment

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; FARGLITAZAR; FOLIC ACID; INFLIXIMAB; INTERFERON; LOSARTAN; MELATONIN; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLTIPRAZ; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; S ADENOSYLMETHIONINE; SALSALATE; TACROLIMUS; TAURINE; URSODEOXYCHOLIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; AUTACOID; IMMUNOSUPPRESSIVE AGENT;

ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; ENIN ANGIOTENSIN ALDOSTERONE SYSTEM; HEPATITIS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FIBROSIS; NEEDLE BIOPSY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; HEPATITIS C, CHRONIC; IMMUNOLOGY; LIVER; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; LIVER; LIVER CIRRHOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84896826716     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i10.2515     Document Type: Article

References (236)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/ j.gastro.2008.03.003]
2. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206 [PMID: 21497738 DOI: 10.1016/j.bpg.2011.02.005]
3. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004; 39: 1631-1638 [PMID: 15185304 DOI: 10.1002/hep.20235]
4. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998; 43: 2573-2576 [PMID: 9881484]
5. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999; 117: 1229-1233 [PMID: 10535887]
6. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378-386 [PMID: 9922319]
7. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-1137 [PMID: 11050066 DOI: 10.1053/jhep.2000.19347]
8. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, Fried MW. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35: 749-755 [PMID: 11738102]
9. Abergel A, Darcha C, Chevallier M, Ughetto S, Henquell C, Pol S, de Ledinghen V, Canva V, Bronowicki JP, Tran A, Martineau N, Lafeuille H, Dechelotte P, Bommelaer G, Bonny C. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol 2004; 16: 1219-1227 [PMID: 15489585]
10. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, Pol S. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403 [PMID: 18794559]
11. Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993; 18: 15-23 [PMID: 7688011]
12. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981-985 [PMID: 9412303]
13. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001; 32: 428-430 [PMID: 11319316]
14. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 646-652 [PMID: 15030981 DOI: 10.1016/j.jhep.2004.01.009]
15. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali S, Rakhshani N, Tavangar SM, Sedaghat M, Alimohamadi SM. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50: 547-551 [PMID: 15810640]
16. Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology 1988; 8: 1679-1683 [PMID: 2461338]
17. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055 [PMID: 7564784]
18. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-857 [PMID: 8608895]
19. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-288, 288. e1 [PMID: 19948249 DOI: 10.1016/j.cgh.2009.11.018]
20. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840-849; quiz e12 [PMID: 21129375 DOI: 10.1053/j.gastro.2010.11.050]
21. Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011; 140: 1990-1999 [PMID: 21419770 DOI: 10.1053/ j.gastro.2011.03.010]
22. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol 2008; 2: 803-816 [PMID: 19090740 DOI: 10.1586/17474124.2.6.803]
23. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011; 4: 391-417 [PMID: 22043231 DOI: 10.1177/1756283X11413002]
24. Ahmad A, Ahmad R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol 2012; 18: 155-167 [PMID: 22626794 DOI: 10.4103/1319-3767.96445]
25. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989; 84: 1780-1785 [PMID: 2556445 DOI: 10.1172/JCI114362]
26. Bachem MG, Melchior R, Gressner AM. The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. J Clin Chem Clin Biochem 1989; 27: 555-565 [PMID: 2607320]
27. Czaja MJ, Weiner FR, Flanders KC, Giambrone MA, Wind R, Biempica L, Zern MA. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol 1989; 108: 2477-2482 [PMID: 2500447]
28. Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994; 94: 1563-1569 [PMID: 7929832 DOI: 10.1172/ JCI117497]
29. Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, Desmoulière A. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006; 38: 135-151 [PMID: 16257564 DOI: 10.1016/j.biocel.2005.08.021]
30. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S. TGF-beta/Smad signaling in the injured liver. Z Gastroenterol 2006; 44: 57-66 [PMID: 16397841 DOI: 10.1055/s-2005-858989]
31. Inagaki Y, Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56: 284-292 [PMID: 17303605 DOI: 10.1136/ gut.2005.088690]
32. Hayashi H, Sakai T. Biological Significance of Local TGF-β Activation in Liver Diseases. Front Physiol 2012; 3: 12 [PMID: 22363291 DOI: 10.3389/fphys.2012.00012]
33. Presser LD, McRae S, Waris G. Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion. PLoS One 2013; 8: e56367 [PMID: 23437118 DOI: 10.1371/journal. pone.0056367]
34. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 2003; 285: G949-G958 [PMID: 12829440 DOI: 10.1152/ajpgi.00215.2003]
35. Hellerbrand SC, Tsukamoto H, Brenner DA, Rippe RA. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology 1996; 24: 670-676 [PMID: 8781341 DOI: 10.1002/hep.510240333]
36. Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, Modlin RL, Liblau RS, Gressner AM, Kaufmann SH. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007; 26: 117-129 [PMID: 17239632 DOI: 10.1016/j.immuni.2006.11.011]
37. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, Friedman SL. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127: 870-882 [PMID: 15362042]
38. Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 2005; 128: 138-146 [PMID: 15633130]
39. Tanaka H, Leung PS, Kenny TP, Gershwin ME, Bowlus CL. Immunological orchestration of liver fibrosis. Clin Rev Allergy Immunol 2012; 43: 220-229 [PMID: 22695942 DOI: 10.1007/ s12016-012-8323-1]
40. Hintermann E, Ehser J, Bayer M, Pfeilschifter JM, Christen U. Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6. J Autoimmun 2013; 44: 49-60 [PMID: 23809878 DOI: 10.1016/j.jaut.2013.05.001]
41. Lemoinne S, Cadoret A, El Mourabit H, Thabut D, Housset C. Origins and functions of liver myofibroblasts. Biochim Biophys Acta 2013; 1832: 948-954 [PMID: 23470555 DOI: 10.1016/ j.bbadis.2013.02.019]
42. Xie G, Karaca G, Swiderska-Syn M, Michelotti GA, Kruger L, Chen Y, Premont RT, Choi SS, Diehl AM. Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice. Hepatology 2013; Epub ahead of print [PMID: 23703657 DOI: 10.1002/hep.26511]
43. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, Pradere JP, Friedman RA, Schwabe RF. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 2012; 143: 1073-1083. e22 [PMID: 22750464 DOI: 10.1053/j.gastro.2012.06.036]
44. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, Evans SM, Dillmann W, Glass CK, Brenner DA. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA 2012; 109: 9448-9453 [PMID: 22566629 DOI: 10.1073/pnas.1201840109]
45. Friedman SL. Fibrogenic cell reversion underlies fibrosis regression in liver. Proc Natl Acad Sci USA 2012; 109: 9230-9231 [PMID: 22645354 DOI: 10.1073/pnas.1206645109]
46. Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Ar-teel GE, Gäbele E, Rusyn I, Yamashina S, Froh M, Adachi Y, Iimuro Y, Bradford BU, Smutney OM, Connor HD, Mason RP, Goyert SM, Peters JM, Gonzalez FJ, Samulski RJ, Thurman RG. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med 2001; 31: 1544-1549 [PMID: 11744328]
47. Bhogal RH, Curbishley SM, Weston CJ, Adams DH, Afford SC. Reactive oxygen species mediate human hepatocyte injury during hypoxia/reoxygenation. Liver Transpl 2010; 16: 1303-1313 [PMID: 21031546 DOI: 10.1002/lt.22157]
48. Tanaka H, Fujita N, Sugimoto R, Urawa N, Horiike S, Kobayashi Y, Iwasa M, Ma N, Kawanishi S, Watanabe S, Kaito M, Takei Y. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer 2008; 98: 580-586 [PMID: 18231107 DOI: 10.1038/sj.bjc.6604204]
49. Sanz-Cameno P, Medina J, García-Buey L, García-Sánchez A, Borque MJ, Martín-Vílchez S, Gamallo C, Jones EA, Moreno-Otero R. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol 2002; 37: 723-729 [PMID: 12445411]
50. Desmoulière A, Darby I, Costa AM, Raccurt M, Tuchweber B, Sommer P, Gabbiani G. Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab Invest 1997; 76: 765-778 [PMID: 9194853]
51. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821-831 [PMID: 8608892]
52. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgeirsson SS, Fukui H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000; 32: 1248-1254 [PMID: 11093731 DOI: 10.1053/jhep.2000.20521]
53. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16: 1009-1017 [PMID: 20818376 DOI: 10.1038/nm.2208]
54. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-478 [PMID: 10930382]
55. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138: 705-714, 714. e1-4 [PMID: 19843474 DOI: 10.1053/j.gastro.2009.10.002]
56. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G245-G249 [PMID: 10915630]
57. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997; 26: 1521-1529 [PMID: 9397993 DOI: 10.1002/hep.510260620]
58. Czaja MJ, Ding WX, Donohue TM, Friedman SL, Kim JS, Komatsu M, Lemasters JJ, Lemoine A, Lin JD, Ou JH, Perlmutter DH, Randall G, Ray RB, Tsung A, Yin XM. Functions of autophagy in normal and diseased liver. Autophagy 2013; 9: 1131-1158 [PMID: 23774882 DOI: 10.4161/auto.25063]
59. Hernández-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, Czaja MJ, Friedman SL. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 2012; 142: 938-946 [PMID: 22240484 DOI: 10.1053/j.gastro.2011.12.044]
60. Hernández-Gea V, Friedman SL. Autophagy fuels tissue fibrogenesis. Autophagy 2012; 8: 849-850 [PMID: 22617442 DOI: 10.4161/auto.19947]
61. Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD, Sands E, Suliman I, Trim N, Knorr A, Arthur MJ, Benyon RC, Iredale JP. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126: 1795-1808 [PMID: 15188175]
62. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000; 124: 1599-1607 [PMID: 11079009]
63. Wanless IR. Use of corticosteroid therapy in autoimmune hepatitis resulting in the resolution of cirrhosis. J Clin Gastroenterol 2001; 32: 371-372 [PMID: 11319303]
64. Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971; 16: 1082-1086 [PMID: 5135770]
65. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20 [PMID: 8020885]
66. Theodossi A, Skene AM, Portmann B, Knill-Jones RP, Patrick RS, Tate RA, Kealey W, Jarvis KJ, O'Brian DJ, Williams R. Observer variation in assessment of liver biopsies including analysis by kappa statistics. Gastroenterology 1980; 79: 232-241 [PMID: 7399228]
67. Westin J, Lagging LM, Wejstål R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 183-187 [PMID: 10395036]
68. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457 [PMID: 14647056 DOI: 10.1016/j.hep.2003.09.022]
69. McCullough AJ, Stassen WN, Wiesner RH, Czaja AJ. Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity. Hepatology 1987; 7: 49-54 [PMID: 3492417]
70. McCullough AJ, Stassen WN, Wiesner RH, Czaja AJ. Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis. J Lab Clin Med 1987; 109: 55-61 [PMID: 3794515]
71. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122: 1525-1528 [PMID: 11984538]
72. Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M, Schuppan D. Hepatitis C virusreplicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005; 129: 246-258 [PMID: 16012951]
73. Shin JY, Hur W, Wang JS, Jang JW, Kim CW, Bae SH, Jang SK, Yang SH, Sung YC, Kwon OJ, Yoon SK. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med 2005; 37: 138-145 [PMID: 15886528 DOI: 10.1038/emm.2005.19]
74. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004; 126: 529-540 [PMID: 14762790]
75. Bonacchi A, Petrai I, Defranco RM, Lazzeri E, Annunziato F, Efsen E, Cosmi L, Romagnani P, Milani S, Failli P, Batignani G, Liotta F, Laffi G, Pinzani M, Gentilini P, Marra F. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 2003; 125: 1060-1076 [PMID: 14517790]
76. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-1832 [PMID: 8253358]
77. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host-and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206 [PMID: 9722200]
78. Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, Sutti S, Marrone A, Ruggiero G, Albano E, Adinolfi LE. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 2008; 48: 399-406 [PMID: 18164507 DOI: 10.1016/j.jhep.2007.10.011]
79. Haque M, Yoshida EM. Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Ann Hepatol 2009; 8: 78-79 [PMID: 19221541]
80. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007; 1: 113-128 [PMID: 19072440 DOI: 10.1586/17474124.1.1.113]
81. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72. e4 [PMID: 20451521 DOI: 10.1053/ j.gastro.2010.04.053]
82. Czaja AJ. Drug choices in autoimmune hepatitis: part A--Steroids. Expert Rev Gastroenterol Hepatol 2012; 6: 603-615 [PMID: 23061711 DOI: 10.1586/egh.12.40]
83. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996; 10 Suppl 2: 81-90; discussion 91-92 [PMID: 8899106]
84. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109: 16-22 [PMID: 10969176]
85. Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod Asp Immunobiol 2001; 2: 78-82
86. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996; 60: 563-572 [PMID: 8929546]
87. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44: 61-98 [PMID: 15634032]
88. Migita K, Eguchi K, Kawabe Y, Nakamura T, Shirabe S, Tsukada T, Ichinose Y, Nakamura H, Nagataki S. Apoptosis induction in human peripheral blood T lymphocytes by highdose steroid therapy. Transplantation 1997; 63: 583-587 [PMID: 9047155]
89. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250 [PMID: 10644669]
90. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-549 [PMID: 9691091]
91. Parrelli JM, Meisler N, Cutroneo KR. Identification of a glucocorticoid response element in the human transforming growth factor beta 1 gene promoter. Int J Biochem Cell Biol 1998; 30: 623-627 [PMID: 9693962]
92. Centrella M, McCarthy TL, Canalis E. Glucocorticoid regulation of transforming growth factor beta 1 activity and binding in osteoblast-enriched cultures from fetal rat bone. Mol Cell Biol 1991; 11: 4490-4496 [PMID: 1875934]
93. Shukla A, Meisler N, Cutroneo KR. Perspective article: transforming growth factor-beta: crossroad of glucocorticoid and bleomycin regulation of collagen synthesis in lung fibroblasts. Wound Repair Regen 1999; 7: 133-140 [PMID: 10417748]
94. Bolkenius U, Hahn D, Gressner AM, Breitkopf K, Dooley S, Wickert L. Glucocorticoids decrease the bioavailability of TGF-beta which leads to a reduced TGF-beta signaling in hepatic stellate cells. Biochem Biophys Res Commun 2004; 325: 1264-1270 [PMID: 15555563 DOI: 10.1016/j.bbrc.2004.10.164]
95. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-538 [PMID: 16496338 DOI: 10.1002/hep.21074]
96. Melgert BN, Olinga P, Van Der Laan JM, Weert B, Cho J, Schuppan D, Groothuis GM, Meijer DK, Poelstra K. Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 2001; 34: 719-728 [PMID: 11584368 DOI: 10.1053/jhep.2001.27805]
97. Czaja AJ. Drug choices in autoimmune hepatitis: part B--Nonsteroids. Expert Rev Gastroenterol Hepatol 2012; 6: 617-635 [PMID: 23061712 DOI: 10.1586/egh.12.38]
98. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30: 358-363 [PMID: 2341582]
99. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-339 [PMID: 1451710]
100. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000; 47: 63-83 [PMID: 10878284]
101. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-743 [PMID: 15354273]
102. Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev Gastroenterol Hepatol 2008; 2: 23-34 [PMID: 19072367 DOI: 10.1586/17474124.2.1.23]
103. de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 686-694 [PMID: 18043678 DOI: 10.1038/ncpgasthep1000]
104. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, Strand D, Tanaka S, Galle PR, Bustelo XR, Neurath MF. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176: 640-651 [PMID: 16365460]
105. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-1145 [PMID: 12697733 DOI: 10.1172/JCI16432]
106. Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007; 56: 293-303 [PMID: 16956919 DOI: 10.1136/ gut.2005.090464]
107. Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR. Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment Pharmacol Ther 2011; 33: 115-126 [PMID: 21083588 DOI: 10.1111/ j.1365-2036.2010.04499.x]
108. Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn WJ, Egan LJ. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 2005; 312: 537-545 [PMID: 15388785 DOI: 10.1124/jpet.104.074815]
109. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23584]
110. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-963 [PMID: 7666914]
111. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-515 [PMID: 17403191 DOI: 10.1111/ j.1478-3231.2007.01444.x]
112. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118 [PMID: 10878285]
113. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 Suppl 1: s2-s8 [PMID: 15803924]
114. Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W. Antifibrotic actions of mycophenolic acid. Clin Transplant 2006; 20 Suppl 17: 25-29 [PMID: 17100698 DOI: 10.1111/j.1399-0012.2006.00597.x]
115. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, Aoshima M, Hasegawa T, Makino I. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490-495 [PMID: 9641646]
116. Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Ando M, Sakaguchi K, Yamamoto K. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int 2009; 3: 556-562 [PMID: 19847577 DOI: 10.1007/ s12072-009-9155-9]
117. Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011; 46: 1136-1141 [PMID: 21597932 DOI: 10.1007/s00535-011-0421-y]
118. Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548-1554 [PMID: 1674105 DOI: 10.1056/ NEJM199105303242204]
119. Abuaf N, Lunel F, Giral P, Borotto E, Laperche S, Poupon R, Opolon P, Huraux JM, Homberg JC. Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol 1993; 18: 359-364 [PMID: 8228130]
120. Parés A, Caballería L, Rodés J, Bruguera M, Rodrigo L, García-Plaza A, Berenguer J, Rodríguez-Martínez D, Mercader J, Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32: 561-566 [PMID: 10782903]
121. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301 [PMID: 9695990 DOI: 10.1002/hep.510280203]
122. Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006; 44: 400-406 [PMID: 16356577 DOI: 10.1016/j.jhep.2005.10.017]
123. Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, Baldo V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100: 1516-1522 [PMID: 15984974 DOI: 10.1111/j.1572-0241.2005.41841.x]
124. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 525-531 [PMID: 12198643 DOI: 10.1053/jhep.2002.36088]
125. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-1156 [PMID: 8175136]
126. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-1199 [PMID: 11093724 DOI: 10.1053/jhep.2000.20240]
127. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122: 652-658 [PMID: 11874998]
128. Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon RE, Poupon R. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int 2004; 24: 187-193 [PMID: 15189267 DOI: 10.1111/ j.1478-3231.2004.0918.x]
129. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007; 102: 1244-1250 [PMID: 17319931 DOI: 10.1111/j.1572-0241.2007.01136.x]
130. Neuhauser M, Bjornsson E, Treeprasertsuk S, Enders F, Silveira M, Talwalkar J, Lindor K. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010; 105: 345-353 [PMID: 19888204 DOI: 10.1038/ajg.2009.616]
131. Beuers U, Boberg KM, Chapman RW, Chazouilleres O, Invernizzi P, Jones DEJ, Lammert F, Pares A, Trauner M. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267 [PMID: 19501929 DOI: 10.1016/j.jhep.2009.04.009]
132. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385 [PMID: 21067838 DOI: 10.1016/j.jhep.2010.09.002]
133. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl 1994; 204: 1-15 [PMID: 7824870]
134. Trauner M, Fickert P, Halilbasic E, Moustafa T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 2008; 158: 542-548 [PMID: 18998069 DOI: 10.1007/s10354-008-0592-1]
135. Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 1993; 104: 1736-1744 [PMID: 8388838]
136. Heuman DM, Bajaj RS, Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. J Lipid Res 1996; 37: 562-573 [PMID: 8728319]
137. Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001; 33: 1206-1216 [PMID: 11343250 DOI: 10.1053/jhep.2001.24034]
138. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufmann SH, Gores GJ. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103: 137-145 [PMID: 9884343 DOI: 10.1172/JCI4765]
139. Ramani K, Tomasi ML, Yang H, Ko K, Lu SC. Mechanism and significance of changes in glutamate-cysteine ligase expression during hepatic fibrogenesis. J Biol Chem 2012; 287: 36341-36355 [PMID: 22942279 DOI: 10.1074/jbc.M112.370775]
140. Liang TJ, Yuan JH, Tan YR, Ren WH, Han GQ, Zhang J, Wang LC, Qin CY. Effect of ursodeoxycholic acid on TGF beta1/Smad signaling pathway in rat hepatic stellate cells. Chin Med J (Engl) 2009; 122: 1209-1213 [PMID: 19493473]
141. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/-mice. Hepatology 2009; 49: 1972-1981 [PMID: 19475687 DOI: 10.1002/hep.22891]
142. Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, Steinbach JH, Schteingart CD, Olinga P, Groothuis GM. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 2005; 42: 1391-1398 [PMID: 16317695 DOI: 10.1002/hep.20943]
143. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-481 [PMID: 16472600 DOI: 10.1053/j.gastro.2005.10.018]
144. Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986; 90: 837-852 [PMID: 3949115]
145. Fickert P, Stöger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, Tsybrovskyy O, Jaeschke H, Zatloukal K, Denk H, Trauner M. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 2007; 171: 525-536 [PMID: 17600122 DOI: 10.2353/ajpath. 2007.061133]
146. Sánchez-Muñoz D, Castellano-Megías VM, Romero-Gómez M. Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis. Dig Liver Dis 2007; 39: 262-266 [PMID: 17270507 DOI: 10.1016/ j.dld.2006.12.004]
147. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41: 809-818 [PMID: 15793848 DOI: 10.1002/hep.20650]
148. Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol 2007; 5: 898-907 [PMID: 17678840 DOI: 10.1016/j.cgh.2007.05.031]
149. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017-1044 [PMID: 19243014 DOI: 10.1002/hep.22742]
150. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J, Ratziu V, Poynard T. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-1896 [PMID: 16931569 DOI: 10.1373/clinchem.2006.070961]
151. Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Curr Hepat Rep 2011; 10: 87-97 [PMID: 21654911 DOI: 10.1007/s11901-011-0096-0]
152. Jarcuska P, Janicko M, Veselíny E, Jarcuska P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta 2010; 411: 1009-1017 [PMID: 20399764 DOI: 10.1016/ j.cca.2010.04.009]
153. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713 [PMID: 14698338]
154. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008; 47: 332-342 [PMID: 18161879 DOI: 10.1002/hep.21972]
155. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201]
156. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699 [PMID: 7560864]
157. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435 [PMID: 7308988]
158. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-244 [PMID: 12873821]
159. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003; 38: 1356-1358 [PMID: 14647044 DOI: 10.1016/j.hep.2003.10.010]
160. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002; 6: 685-705 [PMID: 12362575]
161. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010; 51: 585-594 [PMID: 20101752 DOI: 10.1002/hep.23315]
162. Canafax DM, Ascher NL. Cyclosporine immunosuppression. Clin Pharm 1983; 2: 515-524 [PMID: 6360494]
163. Martínez-Martínez S, Redondo JM. Inhibitors of the calcineurin/ NFAT pathway. Curr Med Chem 2004; 11: 997-1007 [PMID: 15078162]
164. Pissaia A, Aoudjehane L, Ben Othman S, Scatton O, Soubrane O, Housset C, Calmus Y, Conti F. Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor β on human intrahepatic fibroblasts cultured in vitro. Transplant Proc 2010; 42: 4343-4346 [PMID: 21168695 DOI: 10.1016/j.transproceed.2010.09.124]
165. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984; 87: 1222-1227 [PMID: 6489694]
166. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51: 161-167 [PMID: 19446908 DOI: 10.1016/j.jhep.2009.02.026]
167. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29: 816-823 [PMID: 19018980 DOI: 10.1111/j.1478-3231.2008.01904.x]
168. Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci 2010; 55: 1761-1769 [PMID: 20428945 DOI: 10.1007/s10620-010-1243-0]
169. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832 [PMID: 9121257]
170. Colmenero J, Bataller R, Sancho-Bru P, Domínguez M, Moreno M, Forns X, Bruguera M, Arroyo V, Brenner DA, Ginès P. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 2009; 297: G726-G734 [PMID: 19628656 DOI: 10.1152/ ajpgi.00162.2009]
171. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397 [PMID: 15122768 DOI: 10.1002/ hep.20206]
172. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, Valesini G. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519-1520 [PMID: 16162908 DOI: 10.1136/ard.2004.032821]
173. Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J, Costa Santos C. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 2008; 14: 723-725 [PMID: 17929297 DOI: 10.1002/ ibd.20293]
174. Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol 2009; 34: 421-422 [PMID: 19309375 DOI: 10.1111/j.1365-2230.2008.03088.x]
175. Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, Shah V. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004; 99: 255-260 [PMID: 15046213]
176. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960 [PMID: 18848937 DOI: 10.1053/j.gastro.2008.08.057]
177. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648 [PMID: 11113085]
178. Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs 2006; 15: 307-315 [PMID: 16503766 DOI: 10.1517/13543784.15.3.307]
179. McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, Rockey D, Husa P, Chuang WL, Levine R, Jonas M, Theodore D, Brigandi R, Webster A, Schultz M, Watson H, Stancil B, Gardner S. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 2010; 138: 1365-1373, 1373. e1-2 [PMID: 20004661 DOI: 10.1053/j.gastro.2009.12.003]
180. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, Kim SG. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 2002; 16: 1988-1990 [PMID: 12397085 DOI: 10.1096/fj.02-0406fje]
181. Kim SG, Kim YM, Choi JY, Han JY, Jang JW, Cho SH, Um SH, Chon CY, Lee DH, Jang JJ, Yu E, Lee YS. Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial. J Pharm Pharmacol 2011; 63: 627-635 [PMID: 21492164 DOI: 10.1111/ j.2042-7158.2011.01259.x]
182. Weerachayaphorn J, Luo Y, Mennone A, Soroka CJ, Harry K, Boyer JL. Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice. J Hepatol 2014; 60: 160-166 [PMID: 23978715 DOI: 10.1016/j.jhep.2013.08.015]
183. Vos TA, Van Goor H, Tuyt L, De Jager-Krikken A, Leuvenink R, Kuipers F, Jansen PL, Moshage H. Expression of inducible nitric oxide synthase in endotoxemic rat hepatocytes is dependent on the cellular glutathione status. Hepatology 1999; 29: 421-426 [PMID: 9918918 DOI: 10.1002/ hep.510290231]
184. Oliveira CP, Alves VA, Lima VM, Stefano JT, Debbas V, Sá SV, Wakamatsu A, Corrêa-Giannella ML, de Mello ES, Havaki S, Tiniakos DG, Marinos E, de Oliveira MG, Giannella-Neto D, Laurindo FR, Caldwell S, Carrilho FJ. Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob mice. Biochem Pharmacol 2007; 74: 290-297 [PMID: 17524368 DOI: 10.1016/ j.bcp.2007.04.013]
185. Ronis MJ, Butura A, Sampey BP, Shankar K, Prior RL, Korourian S, Albano E, Ingelman-Sundberg M, Petersen DR, Badger TM. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic Biol Med 2005; 39: 619-630 [PMID: 16085180 DOI: 10.1016/ j.freeradbiomed.2005.04.011]
186. Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM, Ronis MJ. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr 2008; 138: 1872-1879 [PMID: 18806095]
187. Bémeur C, Vaquero J, Desjardins P, Butterworth RF. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms. Metab Brain Dis 2010; 25: 241-249 [PMID: 20431929 DOI: 10.1007/s11011-010-9201-2]
188. Setshedi M, Longato L, Petersen DR, Ronis M, Chen WC, Wands JR, de la Monte SM. Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res 2011; 35: 2139-2151 [PMID: 21790669 DOI: 10.1111/ j.1530-0277.2011.01569.x]
189. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998; 27: 1265-1274 [PMID: 9581680 DOI: 10.1002/ hep.510270512]
190. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-1089 [PMID: 10406187]
191. de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008; 38: 159-165 [PMID: 18197877 DOI: 10.1111/j.1872-034X.2007.00215.x]
192. Feld JJ, Modi AA, El-Diwany R, Rotman Y, Thomas E, Ahlenstiel G, Titerence R, Koh C, Cherepanov V, Heller T, Ghany MG, Park Y, Hoofnagle JH, Liang TJ. S-adenosyl methionine improves early viral responses and interferonstimulated gene induction in hepatitis C nonresponders. Gastroenterology 2011; 140: 830-839 [PMID: 20854821 DOI: 10.1053/j.gastro.2010.09.010]
193. Vercelino R, Crespo I, de Souza GF, Cuevas MJ, de Oliveira MG, Marroni NP, González-Gallego J, Tuñón MJ. S-nitroso-N-acetylcysteine attenuates liver fibrosis in cirrhotic rats. J Mol Med (Berl) 2010; 88: 401-411 [PMID: 20062961 DOI: 10.1007/s00109-009-0577-6]
194. Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des 2011; 17: 3120-3140 [PMID: 21902661]
195. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60: 6-20 [PMID: 12613655]
196. Majano PL, Medina J, Zubía I, Sunyer L, Lara-Pezzi E, Maldonado-Rodríguez A, López-Cabrera M, Moreno-Otero R. N-Acetyl-cysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. J Hepatol 2004; 40: 632-637 [PMID: 15030979 DOI: 10.1016/j.jhep.2003.12.009]
197. Majano PL, García-Monzón C, García-Trevijano ER, Corrales FJ, Cámara J, Ortiz P, Mato JM, Avila MA, Moreno-Otero R. S-Adenosylmethionine modulates inducible nitric oxide synthase gene expression in rat liver and isolated hepatocytes. J Hepatol 2001; 35: 692-699 [PMID: 11738094]
198. Parola M, Leonarduzzi G, Biasi F, Albano E, Biocca ME, Poli G, Dianzani MU. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology 1992; 16: 1014-1021 [PMID: 1398481]
199. Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992; 308: 267-270 [PMID: 1505665]
200. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-1672 [PMID: 11564008]
201. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490 [PMID: 14638353 DOI: 10.1111/ j.1572-0241.2003.08699.x]
202. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
203. McCarty MF. Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease. Med Hypotheses 2011; 77: 550-556 [PMID: 21764223 DOI: 10.1016/ j.mehy.2011.06.029]
204. Barak AJ, Beckenhauer HC, Junnila M, Tuma DJ. Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res 1993; 17: 552-555 [PMID: 8333583]
205. Samara K, Liu C, Soldevila-Pico C, Nelson DR, Abdelmalek MF. Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. Dig Dis Sci 2006; 51: 1226-1229 [PMID: 16944015 DOI: 10.1007/s10620-006-8038-3]
206. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-2717 [PMID: 11569700 DOI: 10.1111/j.1572-0241.2001.04129.x]
207. Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KD. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50: 1818-1826 [PMID: 19824078 DOI: 10.1002/hep.23239]
208. Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, Colmenero J, Nicolás JM, Jiménez W, Weich N, Gutiérrez-Ramos JC, Arroyo V, Rodés J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117-125 [PMID: 12851877]
209. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol 1997; 59: 395-412 [PMID: 9074770 DOI: 10.1146/annurev.physiol.59.1.395]
210. Weber KT, Sun Y, Katwa LC, Cleutjens JP. Tissue repair and angiotensin II generated at sites of healing. Basic Res Cardiol 1997; 92: 75-78 [PMID: 9166984]
211. Weber KT, Sun Y, Katwa LC. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol 1997; 29: 31-42 [PMID: 9076939]
212. Katwa LC, Campbell SE, Tyagi SC, Lee SJ, Cicila GT, Weber KT. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 1997; 29: 1375-1386 [PMID: 9201623 DOI: 10.1006/jmcc.1997.0376]
213. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, Takahashi M, Akisawa N, Iwasaki S, Oben JA, Onishi S. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45: 1375-1381 [PMID: 17518368 DOI: 10.1002/hep.21638]
214. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148-155 [PMID: 11438504]
215. Zimmermann H, Reichen J, Zimmermann A, Sägesser H, Thenisch B, Höflin F. Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat. Gastroenterology 1992; 103: 579-589 [PMID: 1634077]
216. Dunn MA, Cheever AW, Paglia LM, Kelly EP, Duvall RH, Andrade ZA, Goldner FH. Reversal of advanced liver fibrosis in rabbits with Schistosomiasis japonica. Am J Trop Med Hyg 1994; 50: 499-505 [PMID: 8166357]
217. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Fléjou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Lévy P. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344: 418-423 [PMID: 11172178 DOI: 10.1056/NEJM200102083440604]
218. Powell LW, Kerr JF. Reversal of "cirrhosis" in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas Ann Med 1970; 19: 54-57 [PMID: 5505522]
219. Falkmer S, Samuelson G, Sjölin S. Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease. Pediatrics 1970; 45: 260-268 [PMID: 5413388]
220. Soyer MT, Ceballos R, Aldrete JS. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery 1976; 79: 601-604 [PMID: 1265672]
221. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136: 667-672 [PMID: 11992302]
222. Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997; 126: 682-688 [PMID: 9139553]
223. Friedman SL, Bansal MB. Reversal of hepatic fibrosis--fact or fantasy? Hepatology 2006; 43: S82-S88 [PMID: 16447275 DOI: 10.1002/hep.20974]
224. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-627 [PMID: 6745850]
225. Kanzler S, Gerken G, Löhr H, Galle PR, Meyer zum Büschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34: 354-355 [PMID: 11281572]
226. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433 [PMID: 15990196 DOI: 10.1016/j.jhep.2005.04.009]
227. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/ hep.23190]
228. Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-1629 [PMID: 21757447 DOI: 10.1136/ gut.2010.235259]
229. Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep 2010; 9: 91-98 [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7]
230. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-1516 [PMID: 15307869 DOI: 10.1111/j.1572-0241.2004.30457.x]
231. Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamaoto R, Ikeda H, Sakai N, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951-957 [PMID: 16143423 DOI: 10.1016/j.jhep.2005.06.006]
232. Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006; 24: 1197-1205 [PMID: 17014578 DOI: 10.1111/ j.1365-2036.2006.03113.x]
233. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-1012 [PMID: 17319926 DOI: 10.1111/ j.1572-0241.2007.01153.x]
234. van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, Beuers U, van Buuren HR, de Man RA, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Mulder CJ, van Nieuwkerk KM, Bouma G. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58: 141-147 [PMID: 22989569 DOI: 10.1016/j.jhep.2012.09.009]
235. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013; 5: 167sr1 [PMID: 23303606 DOI: 10.1126/scitranslmed. 3004700]
236. Manns MP. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology 2011; 140: 1874-1876 [PMID: 21524652 DOI: 10.1053/j.gastro.2011.04.026]